Programmed cell death protein 1 (PD-1) blockade targeting the PD-1 immune checkpoint
has demonstrated unprecedented clinical efficacy in the treatment of advanced cancers …

Cancer cells can escape T-cell-mediated cellular cytotoxicity by exploiting the inhibitory
programmed cell-death protein 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) immune …

Germinal centers (GCs) are confined anatomic regions where rapidly proliferating B cells
undergo somatic mutation and selection and eventual differentiation into memory B cells or …

B cells often constitute abundant cellular components in human tumors. Regulatory B cells
that are functionally defined by their ability to produce IL10 downregulate inflammation and …

Background Endogenous or iatrogenic antitumour immune responses can improve the
course of follicular lymphoma, but might be diminished by immune checkpoints in the tumour …

Harnessing the power of the immune system to recognize and eliminate cancer cells is a
longtime exploration. In the past decade, monoclonal antibody (mAb)-based immune …

Immune evasion is a key strategy adopted by tumor cells to escape the immune system
while promoting their survival and metastatic spreading. Indeed, several mechanisms have …

Therapeutic blockade of immune checkpoint pathways, in particular cytotoxic T-lymphocyte
associated protein 4 and programmed-death 1 (PD-1), has become a paradigm-shifting …

Immunotherapy for the treatment of cancer is rapidly evolving from therapies that globally
and non-specifically simulate the immune system to more targeted activation of individual …

The incidence of lymphoma has gradually increased over previous decades, and it ranks
among the ten most prevalent cancers worldwide. With the development of targeted …